- Home
- ASAN vs SUPN Comparison
ASAN vs SUPN Comparison
Compare ASAN & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASAN | SUPN |
|---|---|---|
| Founded | 2008 | 2005 |
| Country | US | US |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 2.8B |
| IPO Year | 2020 | 2010 |
Fundamental Metrics
Financial Performance| Metric | ASAN | SUPN |
|---|---|---|
| Price | $7.65 | $50.27 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 5 |
| Target Price | $16.17 | ★ $61.60 |
| AVG Volume (30 Days) | ★ 5.1M | 629.2K |
| Earning Date | 03-02-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 5.13 | ★ 6500.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $723,876,000.00 | $392,755,000.00 |
| Revenue This Year | $11.39 | $8.18 |
| Revenue Next Year | $8.48 | $22.15 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 10.94 | N/A |
| 52 Week Low | $7.15 | $29.16 |
| 52 Week High | $22.27 | $57.65 |
Technical Indicators
Market Signals| Indicator | ASAN | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 24.01 | 51.27 |
| Support Level | $7.15 | $49.46 |
| Resistance Level | $7.88 | $51.97 |
| Average True Range (ATR) | 0.57 | 1.58 |
| MACD | -0.09 | 0.11 |
| Stochastic Oscillator | 14.37 | 63.62 |
Price Performance
Historical ComparisonAbout ASAN Asana Inc.
Asana is a work management platform that allows for increased collaboration and visibility across an organization. Delivered via a SaaS-based model, users can track progress across marketing and development initiatives, create and automate workflows, and manage IT approvals. Revenue is generated on a per-seat basis across several pricing tiers. As of fiscal 2025, the company had over 175,000 customers.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.